INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript

Core Insights - INmune Bio is a clinical stage biotechnology company focused on developing therapies for neuroinflammation in neurodegenerative diseases, with its lead program XPro1595 being a first-in-class selective soluble TNF inhibitor [1] Group 1: Clinical Development - The objective of the recent webinar was to demonstrate how the clinical results from the Phase II MINDFuL trial will inform the registration program for XPro1595 [2] - A productive end of Phase II meeting with the FDA confirmed alignment on the core elements of the Phase III registration program [2] Group 2: Trial Design and Outcomes - The MINDFuL trial was a strategic proof-of-concept study designed to address two critical variables: biologic signal and patient selection in Alzheimer's disease [3] - The trial aimed to determine if XPro1595 shows biologic activity in patients with Alzheimer's disease and inflammation biomarkers, and whether the right patient population for a registration trial could be identified [3] - Results indicated that XPro1595 demonstrated biologic activity and validated a precision medicine roadmap for the Phase III registration program [3]